[271 Pages Report] By the end of 2022, the global immunochromatography kits market is anticipated to be worth US$ 8.1 Billion, and it will grow at a CAGR of 4.1% to reach an expected valuation of around US$ 12.1 Billion by the year 2032. Kits dominate the worldwide market in 2021, as a product, with a share of around 72.7%, according to a recent analysis by Future Market Insights.
Market Outlook:
| Data Points | Market Insights |
|---|---|
| Market Value 2022 | US$ 8.1 Billion |
| Market Value 2032 | US$ 12.1 Billion |
| CAGR 2022-2032 | 4.1% |
| Market Share of Top 5 Countries | 60.7% |
| Key Market Players | Abbott Laboratories, PerkinElmer Inc., Danaher Corporation, Bio-rad Laboratories, F. Hoffmann-La Roche AG, bioMérieux SA, Becton, Dickinson and Company, Siemens Healthineers AG, Thermo Fisher Scientific Inc., and QIAGEN |
The lateral flow test or immunochromatography assay is a simple method for determining if the target analyte is present or missing. The immunochromatography test is the most often utilized test in diagnostic laboratories around the world for rapid patient diagnosis and treatment. The goal of immunochromatography kits is to identify whether a target analyte (such as an antigen or an antibody) is present or missing in a sample in a timely and cost-effective manner.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The market value for immunochromatography kits was approximately 22.9% of the overall ~US$ 33.7 Bn of the global immunoassay market in 2021.
The sale of immunochromatography kits expanded at a CAGR of 4.2% from 2012 to 2021.
Immunochromatography kits are unquestionably one of the most effective analytical tools for on-site target identification. Immunochromatography, which is analogous to a lab-in-a-hand, along with other point-of-need diagnostics, has marked a paradigm change from lab-to-lab to lab-to-sample intended to enable faster decision-making and turnaround time. Immunochromatography kits have a number of characteristics that make them a desirable resource for clinical diagnostics, where they can enhance patient care by facilitating faster treatment and diagnosis decisions.
Widespread acceptance of immunochromatography kits is a result of their efficiency, simplicity, relative affordability, and ability to be used by unskilled individuals. Public health continues to be seriously endangered by hepatitis B. According to the World Health Organization's bulletin from 2018, it is estimated that more than 257 million individuals worldwide have chronic hepatitis B infection and that about 9 million have died from liver failure, hepatocellular carcinoma, liver cirrhosis, and other diseases linked to HBV.
The most widely used serological marker for the screening, diagnosis and evaluation of antiviral therapy for hepatitis B is hepatitis B surface antigen (HBsAg), which is the envelope protein of HBV. Due to their numerous benefits, such as ease of use, low cost, and quick turnaround time, immunochromatography kits have been extensively used in HBV screenings, including self-examinations, medical checks, donating blood, and emergency, and epidemiologic surveys.
The prevalence of cancer is gradually rising, which is anticipated to increase the need for efficient diagnostic tools like immunoassay. This method is important for determining oncogenesis and diagnosing cancer in all of its forms, including benign and malignant cancer. Globally, the use of immunoassay-based diagnostics is steadily rising. The control of the epidemic disease is greatly aided by public awareness initiatives that educate the public about the signs of infectious diseases and how to prevent them. As a result, there is a significant demand for immunochromatography kits due to greater patient awareness.
Because of the aforementioned factors, it is anticipated that from 2022 to 2032, the global immunochromatography kits market will expand at a CAGR of 4.1%.
Since there are more infectious pathogens causing dangerous diseases globally, the development and implementation of rapid diagnostic technologies are urgently needed. Early interventions can make a significant difference in the severity of any disease epidemic by reducing the number of cases.
In recent years, researchers have thought about using more difficult and expensive immunoassay techniques, such as radioimmunoassay and ELISA, in place of the construction of quick, precise, and sensitive approaches.
The majority of these approaches rely on agglutination, immunochromatography (ICG), and several molecular methods. In hospitals, clinics, doctor's offices, and clinical labs, ICG tests are utilized for the qualitative and quantitative detection of a wide range of antigens and antibodies. Additional diagnostic alternatives for parasitic diseases are offered by the novel immunochromatography technology, which may be examined and contrasted with existing conventional diagnostic approaches.
For the diagnosis of parasitic infections such as intestinal parasite protozoa, leishmaniasis, filariasis, trypanosomiasis, trichomoniasis, toxoplasmosis, and others, a number of ICTs have been developed. A number of immunochromatography kits based primarily on the detection of several parasite antigens (and antibodies in certain tests) have recently been developed for the diagnosis of parasitic infections, and the findings are encouraging. Researchers for the identification of various parasite infections have recently evaluated Immunochromatography kits.
Although immunochromatography kits have been around for a while and can be used in the field, there is currently no conclusive data on how well they perform in addressing specific diseases. In terms of performance, scientists concur that immunochromatography kits are a potential tool for diagnosing parasite infections and are reasonably reliable in differentiating between positive and negative people.
Immunochromatography kits are thus a potentially valuable supplement to existing diagnostic tools for parasitic illnesses, providing manufacturers with lucrative opportunities for expansion in the global market during the forecast period.
Principal Consultant
Despite being widely used as the gold standard approach, the use of immunochromatography kits has certain drawbacks.
False-negative results can happen as a result of poor specimen quality, such as when the sample is taken at an inopportune time relative to the onset of the illness, or owing to improper specimen handling or shipping to the laboratory department. False positive results might also be the result of contamination or technical aspects.
Since the detection of an immune response to the virus is an indirect indicator of infection, unlike molecular testing, the development of reliable serological tests and their proper application are crucial to support ongoing public health efforts for effective epidemic prevention.
In order to achieve a quantitative improvement using immunochromatography, additional detecting equipment is needed. The immunoassay method also has a lot of disadvantages when used as an easy and affordable sensing method for domestic or personal use.
Additionally, because it is a one-step assay, the total volume in the test is limited, putting a cap on the sensitivity. Moreover, the analysis is reliant on the characteristics of the sample, including sample viscosity. These are some of the factors restraining the market for immunochromatography kits' adoption globally.
With a market share of 82.8% in all of North America in 2021, the USA presently dominates the region and is expected to sustain this growth throughout the forecast period. This can be attributable to two factors: the simple accessibility of technologically enhanced diagnostic tools, as well as the increased demand for diagnostics brought on by the rise in cancer incidence. The high prevalence of infectious diseases including HIV, TB, and influenza in the region is also driving up the demand for treatment and diagnostic services.
China represents roughly 60.1% of the East Asia market in 2021, with growth at a lucrative CAGR of 4.8% throughout the forecast period. The growing aging population within the country, as well as the wide prevalence of chronic and infectious diseases, presents this growth. Moreover, with the rapidly enhancing healthcare structure in the country, the market for immunochromatography kits is set to advance at a high rate over the forecasted years. Moreover, with the advent of the COVID-19 pandemic, the country presented a greater adoption of immunochromatography kits for the rapid detection of the SARS COV-2 antigen, for the effective management of infection and its prevention.
During the forecast years, Germany is projected to grow at a CAGR of nearly 3.7% in the global immunochromatography kits market. Germany holds the presence of established key players within the global immunochromatography space. Key players like Qiagen have posed a dominant hand in the distribution and development of novel point-of-need diagnosis, thus presenting Germany with a larger market share of around 24.9% within the European market, in 2021. Moreover, growing awareness of infection prevention, as well as the presence of reimbursement for treatment, has aided Germany with lucrative growth opportunities during the forecast period.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Kits are expected to present high growth at a CAGR of 4.2% throughout the forecast period. The benefits of immunochromatography kits include a small sample amount, portable devices, and the absence of the requirement for huge and expensive equipment. Immunochromatography kit technology and design today substantially dismiss previous concerns about their specificity, accuracy, and reproducibility.
The application of immunochromatography kits for the detection of infectious diseases holds a share of around 34.5% in 2021, and this segment is expected to display gradual growth over the forecast period. Immunochromatography assays (ICA), which detect antibodies against pathogens, have been routinely utilized to diagnose a variety of infectious diseases. Rapid direct tests (viral protein screening) have an advantage over indirect ELISA tests (serology) in the case of immunocompromised patients since these patients do not have antibody levels that are high enough to be identified, thus propelling demand for immunochromatography kits for infectious disease detection.
Hospital pharmacies held the highest market share value of 36.5% during the year 2021. Being the prime source for the distribution of immunochromatography kits, this segment is expected to expand at a CAGR of 4.0% during the forecast period. Moreover, point-of-care tests are highly useful for repeat follow-up tests to check treatment progress or for continuous monitoring of a specific analyte. Point-of-care testing substantially shortens the turnaround time, which is crucial and very helpful in addressing serious conditions like heart disease.
To increase their market position, major competitors in the immunochromatography kits market are using a variety of organic and inorganic methods, including alliances, mergers, and acquisitions, geographic growth, and strategic collaborations.
Similarly, recent developments related to companies manufacturing immunochromatography kits have been tracked by the team at Future Market Insights, which are available in the full report.
| Attribute | Details |
|---|---|
| Forecast Period | 2022 to 2032 |
| Historical Data Available for | 2012 to 2021 |
| Market Analysis | US$ Million for Value |
| Key Regions Covered | North America, Latin America, Europe, South Asia, East Asia, Oceania, and Middle East & Africa |
| Key Countries Covered | USA, Canada, Brazil, Mexico, Argentina, UK, Germany, Italy, Russia, Spain, France, BENELUX, India, Thailand, Indonesia, Malaysia, Japan, China, South Korea, Australia, New Zealand, Turkey, GCC Countries, North Africa, and South Africa |
| Key Market Segments Covered | Product, Application, Usage, Distribution Channel, and Region |
| Key Companies Profiled |
|
| Pricing | Available upon Request |
The global immunochromatography kits market is estimated to be worth US$ 8.1 Billion in 2022 and is set to expand 1.5X over the next ten years.
The immunochromatography kits market is expected to reach US$ 12.1 Billion by end of 2032 at a CAGR of 4.1%.
Growing geriatric population, rising burden of chronic and infectious diseases, and growing awareness regarding point-of-need diagnostics, are some of the key trends in this market.
By region, North America holds the highest market share generating revenue of close to US$ 3.2 Billion in 2021, in the global immunochromatography kits market.
Europe accounts for about 24.1% of the global immunochromatography kits market in 2021 and is projected to grow with a CAGR of 4.0% during the forecast period.
The US, China, Japan, India, and Germany are the top five countries, which are expected to drive demand in the immunochromatography kits market.
Abbott Laboratories, PerkinElmer Inc., Danaher Corporation, Bio-rad Laboratories, F. Hoffmann-La Roche AG, bioMérieux SA, Becton, Dickinson and Company, Siemens Healthineers AG, Thermo Fisher Scientific Inc., and QIAGEN, are some of the key players in the immunochromatography kits industry.
From 2012 to 2021, the market for immunochromatography kits expanded at the rate of 4.2% CAGR.
The immunochromatography kits market in South Asia is expected to grow at 4.7% CAGR during the forecast period.
East Asia is set to present lucrative growth at a CAGR of 4.9% during the forecasted years.
1. Executive Summary | Immunochromatography Kits Market 1.1. Global Market Outlook 1.2. Demand Side Trends 1.3. Supply Side Trends 1.4. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 2.3. Inclusions and Exclusions 3. Key Market Trends 3.1. Key Trends Impacting the Market 3.2. Product Innovation / Development Trends 4. Key Success Factors 4.1. Product Adoption Analysis 4.2. Regulatory Landscape 4.3. Adoption of Point-of-Care Testing 4.4. PESTEL Analysis 4.5. Porter’s Analysis 5. Market Background 5.1. Macro-Economic Factors 5.1.1. Global GDP Growth Outlook 5.1.2. Global Healthcare Outlook 5.1.3. Global Immunoassay Market Overview 5.2. Forecast Factors - Relevance & Impact 5.2.1. Increasing Prevalence of Chronic and Infectious Diseases 5.2.2. Growing Elderly Population 5.2.3. Rising Adoption of Immunochromatography Kits 5.2.4. Technological Advancements 5.2.5. Presence of Alternative Test Kits as Substitute Products 5.2.6. Product Accessibility and Cost 5.3. Market Dynamics 5.3.1. Drivers 5.3.2. Restraints 5.3.3. Opportunity Analysis 6. COVID-19 Crisis Analysis 6.1. COVID-19 and Impact Analysis 6.1.1. By Product 6.1.2. By Application 6.1.3. By Distribution Channel 6.1.4. By Country 6.2. 2021 Market Scenario 7. Global Market Volume (Units) Analysis 2012 to 2021 and Forecast, 2022 to 2032 7.1. Historical Market Volume (Units) Analysis, 2012 to 2021 7.2. Current and Future Market Volume (Units) Projections, 2022 to 2032 7.2.1. Y-o-Y Growth Trend Analysis 8. Global Market - Pricing Analysis 8.1. Regional Pricing Analysis By Product 8.2. Pricing Break-up 8.2.1. Manufacturer-Level Pricing 8.2.2. Distributor Level Pricing 8.3. Global Average Pricing Analysis Benchmark 8.4. Pricing Assumptions 9. Global Market Demand (in Value or Size in US$ Million) Analysis 2012 to 2021 and Forecast, 2022 to 2032 9.1. Historical Market Value (US$ Million) Analysis, 2012 to 2021 9.2. Current and Future Market Value (US$ Million) Projections, 2022 to 2032 9.2.1. Y-o-Y Growth Trend Analysis 9.2.2. Absolute $ Opportunity Analysis 10. Global Market Analysis By Product 10.1. Introduction / Key Findings 10.2. Historical Market Size (US$ Million) and Volume (Units) Analysis By Product, 2012 to 2021 10.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast By Product, 2022 to 2032 10.3.1. Readers 10.3.2. Kits 10.4. Market Attractiveness Analysis By Product 11. Global Market Analysis By Application 11.1. Introduction / Key Findings 11.2. Historical Market Size (US$ Million) Analysis, By Application, 2012 to 2021 11.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Application, 2022 to 2032 11.3.1. Sexually Transmitted Diseases 11.3.2. Infectious Diseases 11.3.3. Diabetes 11.3.4. Pregnancy Testing 11.3.5. Drug Abuse Testing 11.3.6. Others 11.4. Market Attractiveness Analysis By Application 12. Global Market Analysis By Distribution Channel 12.1. Introduction / Key Findings 12.2. Historical Market Size (US$ Million) Analysis, By Distribution Channel, 2012 to 2021 12.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Distribution Channel, 2022 to 2032 12.3.1. Hospital Pharmacies 12.3.2. Retail Pharmacies 12.3.3. Supermarket/Hypermarket 12.3.4. E-Commerce 12.4. Market Attractiveness Analysis By Distribution Channel 13. Global Market Analysis By Region 13.1. Introduction 13.2. Historical Market Size (US$ Million) and Volume (Units) Analysis By Region, 2012 to 2021 13.3. Current and Future Market Value (US$ Million) and Volume (Units) Projections, 2022 to 2032 13.3.1. North America 13.3.2. Latin America 13.3.3. Europe 13.3.4. East Asia 13.3.5. South Asia 13.3.6. Oceania 13.3.7. Middle East and Africa (MEA) 13.4. Market Attractiveness Analysis By Region 14. North America Market Analysis 14.1. Introduction 14.2. Historical Market Size (US$ Million) Trend and Volume (Units) Analysis By Market Taxonomy, 2012 to 2021 14.3. Current and Future Market Value (US$ Million) and Volume (Units) Analysis and Forecast, By Market Taxonomy 2022 to 2032 14.3.1. By Country 14.3.1.1. The USA 14.3.1.2. Canada 14.3.2. By Product 14.3.3. By Application 14.3.4. By Distribution Channel 14.4. Market Attractiveness Analysis 14.4.1. By Country 14.4.2. By Product 14.4.3. By Application 14.4.4. By Distribution Channel 14.5. Market Trends 14.6. Drivers and Restraints - Impact Analysis 14.7. Country-Level Analysis & Forecast 14.7.1. The USA Market Analysis 14.7.1.1. Introduction 14.7.1.2. Market Analysis and Forecast by Market Taxonomy 14.7.1.2.1. By Product 14.7.1.2.2. By Application 14.7.1.2.3. By Distribution Channel 14.7.2. Canada Market Analysis 14.7.2.1. Introduction 14.7.2.2. Market Analysis and Forecast by Market Taxonomy 14.7.2.2.1. By Product 14.7.2.2.2. By Application 14.7.2.2.3. By Distribution Channel 15. Latin America Market Analysis 15.1. Introduction 15.2. Historical Market Size (US$ Million) Trend and Volume (Units) Analysis By Market Taxonomy, 2012 to 2021 15.3. Current and Future Market Value (US$ Million) and Volume (Units) Analysis and Forecast, By Market Taxonomy 2022 to 2032 15.3.1. By Country 15.3.1.1. Mexico 15.3.1.2. Brazil 15.3.1.3. Argentina 15.3.1.4. Rest of Latin America 15.3.2. By Product 15.3.3. By Application 15.3.4. By Distribution Channel 15.4. Market Attractiveness Analysis 15.4.1. By Country 15.4.2. By Product 15.4.3. By Application 15.4.4. By Distribution Channel 15.5. Market Trends 15.6. Drivers and Restraints - Impact Analysis 15.7. Country-Level Analysis & Forecast 15.7.1. Mexico Market Analysis 15.7.1.1. Introduction 15.7.1.2. Market Analysis and Forecast by Market Taxonomy 15.7.1.2.1. By Product 15.7.1.2.2. By Application 15.7.1.2.3. By Distribution Channel 15.7.2. Brazil Market Analysis 15.7.2.1. Introduction 15.7.2.2. Market Analysis and Forecast by Market Taxonomy 15.7.2.2.1. By Product 15.7.2.2.2. By Application 15.7.2.2.3. By Distribution Channel 15.7.3. Argentina Market Analysis 15.7.3.1. Introduction 15.7.3.2. Market Analysis and Forecast by Market Taxonomy 15.7.3.2.1. By Product 15.7.3.2.2. By Application 15.7.3.2.3. By Distribution Channel 16. Europe Market Analysis 16.1. Introduction 16.2. Historical Market Size (US$ Million) Trend and Volume (Units) Analysis By Market Taxonomy, 2012 to 2021 16.3. Current and Future Market Value (US$ Million) and Volume (Units) Analysis and Forecast, By Market Taxonomy 2022 to 2032 16.3.1. By Country 16.3.1.1. Germany 16.3.1.2. Italy 16.3.1.3. France 16.3.1.4. The UK 16.3.1.5. Spain 16.3.1.6. BENELUX 16.3.1.7. Russia 16.3.1.8. Rest of Europe 16.3.2. By Product 16.3.3. By Application 16.3.4. By Distribution Channel 16.4. Market Attractiveness Analysis 16.4.1. By Country 16.4.2. By Product 16.4.3. By Application 16.4.4. By Distribution Channel 16.5. Market Trends 16.6. Drivers and Restraints - Impact Analysis 16.7. Country-Level Analysis & Forecast 16.7.1. Germany Market Analysis 16.7.1.1. Introduction 16.7.1.2. Market Analysis and Forecast by Market Taxonomy 16.7.1.2.1. By Product 16.7.1.2.2. By Application 16.7.1.2.3. By Distribution Channel 16.7.2. Italy Market Analysis 16.7.2.1. Introduction 16.7.2.2. Market Analysis and Forecast by Market Taxonomy 16.7.2.2.1. By Product 16.7.2.2.2. By Application 16.7.2.2.3. By Distribution Channel 16.7.3. France Market Analysis 16.7.3.1. Introduction 16.7.3.2. Market Analysis and Forecast by Market Taxonomy 16.7.3.2.1. By Product 16.7.3.2.2. By Application 16.7.3.2.3. By Distribution Channel 16.7.4. The UK Market Analysis 16.7.4.1. Introduction 16.7.4.2. Market Analysis and Forecast by Market Taxonomy 16.7.4.2.1. By Product 16.7.4.2.2. By Application 16.7.4.2.3. By Distribution Channel 16.7.5. Spain Market Analysis 16.7.5.1. Introduction 16.7.5.2. Market Analysis and Forecast by Market Taxonomy 16.7.5.2.1. By Product 16.7.5.2.2. By Application 16.7.5.2.3. By Distribution Channel 16.7.6. BENELUX Market Analysis 16.7.6.1. Introduction 16.7.6.2. Market Analysis and Forecast by Market Taxonomy 16.7.6.2.1. By Product 16.7.6.2.2. By Application 16.7.6.2.3. By Distribution Channel 16.7.7. Russia Market Analysis 16.7.7.1. Introduction 16.7.7.2. Market Analysis and Forecast by Market Taxonomy 16.7.7.2.1. By Product 16.7.7.2.2. By Application 16.7.7.2.3. By Distribution Channel 17. East Asia Market Analysis 17.1. Introduction 17.2. Historical Market Size (US$ Million) Trend and Volume (Units) Analysis By Market Taxonomy, 2012 to 2021 17.3. Current and Future Market Value (US$ Million) and Volume (Units) Analysis and Forecast, By Market Taxonomy 2022 to 2032 17.3.1. By Country 17.3.1.1. China 17.3.1.2. Japan 17.3.1.3. South Korea 17.3.2. By Product 17.3.3. By Application 17.3.4. By Distribution Channel 17.4. Market Attractiveness Analysis 17.4.1. By Country 17.4.2. By Product 17.4.3. By Application 17.4.4. By Distribution Channel 17.5. Market Trends 17.6. Drivers and Restraints - Impact Analysis 17.7. Country-Level Analysis & Forecast 17.7.1. China Market Analysis 17.7.1.1. Introduction 17.7.1.2. Market Analysis and Forecast by Market Taxonomy 17.7.1.2.1. By Product 17.7.1.2.2. By Application 17.7.1.2.3. By Distribution Channel 17.7.2. Japan Market Analysis 17.7.2.1. Introduction 17.7.2.2. Market Analysis and Forecast by Market Taxonomy 17.7.2.2.1. By Product 17.7.2.2.2. By Application 17.7.2.2.3. By Distribution Channel 17.7.3. South Korea Market Analysis 17.7.3.1. Introduction 17.7.3.2. Market Analysis and Forecast by Market Taxonomy 17.7.3.2.1. By Product 17.7.3.2.2. By Application 17.7.3.2.3. By Distribution Channel 18. South Asia Market Analysis 18.1. Introduction 18.2. Historical Market Size (US$ Million) Trend and Volume (Units) Analysis By Market Taxonomy, 2012 to 2021 18.3. Current and Future Market Value (US$ Million) and Volume (Units) Analysis and Forecast, By Market Taxonomy 2022 to 2032 18.3.1. By Country 18.3.1.1. India 18.3.1.2. Indonesia 18.3.1.3. Malaysia 18.3.1.4. Thailand 18.3.1.5. Rest of South Asia 18.3.2. By Product 18.3.3. By Application 18.3.4. By Distribution Channel 18.4. Market Attractiveness Analysis 18.4.1. By Country 18.4.2. By Product 18.4.3. By Application 18.4.4. By Distribution Channel 18.5. Market Trends 18.6. Drivers and Restraints - Impact Analysis 18.7. Country-Level Analysis & Forecast 18.7.1. India Market Analysis 18.7.1.1. Introduction 18.7.1.2. Market Analysis and Forecast by Market Taxonomy 18.7.1.2.1. By Product 18.7.1.2.2. By Application 18.7.1.2.3. By Distribution Channel 18.7.2. Indonesia Market Analysis 18.7.2.1. Introduction 18.7.2.2. Market Analysis and Forecast by Market Taxonomy 18.7.2.2.1. By Product 18.7.2.2.2. By Application 18.7.2.2.3. By Distribution Channel 18.7.3. Malaysia Market Analysis 18.7.3.1. Introduction 18.7.3.2. Market Analysis and Forecast by Market Taxonomy 18.7.3.2.1. By Product 18.7.3.2.2. By Application 18.7.3.2.3. By Distribution Channel 18.7.4. Thailand Market Analysis 18.7.4.1. Introduction 18.7.4.2. Market Analysis and Forecast by Market Taxonomy 18.7.4.2.1. By Product 18.7.4.2.2. By Application 18.7.4.2.3. By Distribution Channel 19. Oceania Market Analysis 19.1. Introduction 19.2. Historical Market Size (US$ Million) Trend and Volume (Units) Analysis By Market Taxonomy, 2012 to 2021 19.3. Current and Future Market Value (US$ Million) and Volume (Units) Analysis and Forecast, By Market Taxonomy 2022 to 2032 19.3.1. By Country 19.3.1.1. Australia 19.3.1.2. New Zealand 19.3.2. By Product 19.3.3. By Application 19.3.4. By Distribution Channel 19.4. Market Attractiveness Analysis 19.4.1. By Country 19.4.2. By Product 19.4.3. By Application 19.4.4. By Distribution Channel 19.5. Key Market Participants - Intensity Mapping 19.6. Drivers and Restraints - Impact Analysis 19.7. Country-Level Analysis & Forecast 19.7.1. Australia Market Analysis 19.7.1.1. Introduction 19.7.1.2. Market Analysis and Forecast by Market Taxonomy 19.7.1.2.1. By Product 19.7.1.2.2. By Application 19.7.1.2.3. By Distribution Channel 19.7.2. New Zealand Market Analysis 19.7.2.1. Introduction 19.7.2.2. Market Analysis and Forecast by Market Taxonomy 19.7.2.2.1. By Product 19.7.2.2.2. By Application 19.7.2.2.3. By Distribution Channel 20. Middle East and Africa (MEA) Market Analysis 20.1. Introduction 20.2. Historical Market Size (US$ Million) Trend and Volume (Units) Analysis By Market Taxonomy, 2012 to 2021 20.3. Current and Future Market Value (US$ Million) and Volume (Units) Analysis and Forecast, By Market Taxonomy 2022 to 2032 20.3.1. By Country 20.3.1.1. GCC Countries 20.3.1.2. Turkey 20.3.1.3. North Africa 20.3.1.4. South Africa 20.3.1.5. Rest of Middle East and Africa 20.3.2. By Product 20.3.3. By Application 20.3.4. By Distribution Channel 20.4. Market Attractiveness Analysis 20.4.1. By Country 20.4.2. By Product 20.4.3. By Application 20.4.4. By Distribution Channel 20.5. Market Trends 20.6. Drivers and Restraints - Impact Analysis 20.7. Country-Level Analysis & Forecast 20.7.1. GCC Countries Market Analysis 20.7.1.1. Introduction 20.7.1.2. Market Analysis and Forecast by Market Taxonomy 20.7.1.2.1. By Product 20.7.1.2.2. By Application 20.7.1.2.3. By Distribution Channel 20.7.2. Turkey Market Analysis 20.7.2.1. Introduction 20.7.2.2. Market Analysis and Forecast by Market Taxonomy 20.7.2.2.1. By Product 20.7.2.2.2. By Application 20.7.2.2.3. By Distribution Channel 20.7.3. South Africa Market Analysis 20.7.3.1. Introduction 20.7.3.2. Market Analysis and Forecast by Market Taxonomy 20.7.3.2.1. By Product 20.7.3.2.2. By Application 20.7.3.2.3. By Distribution Channel 20.7.4. North Africa Market Analysis 20.7.4.1. Introduction 20.7.4.2. Market Analysis and Forecast by Market Taxonomy 20.7.4.2.1. By Product 20.7.4.2.2. By Application 20.7.4.2.3. By Distribution Channel 21. Market Structure Analysis 21.1. Market Analysis by Tier of Companies 21.2. Market Share Analysis of Top Players 21.3. Market Presence Analysis 22. Competition Analysis 22.1. Competition Dashboard 22.2. Competition Benchmarking 22.3. Competition Deep Dive 22.3.1. Abbott Laboratories 22.3.1.1. Overview 22.3.1.2. Product Portfolio 22.3.1.3. Sales Footprint 22.3.1.4. Key Financials 22.3.1.5. SWOT Analysis 22.3.1.6. Strategy Overview 22.3.2. PerkinElmer Inc. 22.3.2.1. Overview 22.3.2.2. Product Portfolio 22.3.2.3. Sales Footprint 22.3.2.4. Key Financials 22.3.2.5. SWOT Analysis 22.3.2.6. Strategy Overview 22.3.3. Danaher Corporation 22.3.3.1. Overview 22.3.3.2. Product Portfolio 22.3.3.3. Sales Footprint 22.3.3.4. Key Financials 22.3.3.5. SWOT Analysis 22.3.3.6. Strategy Overview 22.3.4. Bio-Rad Laboratories 22.3.4.1. Overview 22.3.4.2. Product Portfolio 22.3.4.3. Sales Footprint 22.3.4.4. Key Financials 22.3.4.5. SWOT Analysis 22.3.4.6. Strategy Overview 22.3.5. F. Hoffmann-La Roche AG 22.3.5.1. Overview 22.3.5.2. Product Portfolio 22.3.5.3. Sales Footprint 22.3.5.4. Key Financials 22.3.5.5. SWOT Analysis 22.3.5.6. Strategy Overview 22.3.6. BioMérieux SA 22.3.6.1. Overview 22.3.6.2. Product Portfolio 22.3.6.3. Sales Footprint 22.3.6.4. Key Financials 22.3.6.5. SWOT Analysis 22.3.6.6. Strategy Overview 22.3.7. Becton, Dickinson, and Company 22.3.7.1. Overview 22.3.7.2. Product Portfolio 22.3.7.3. Sales Footprint 22.3.7.4. Key Financials 22.3.7.5. SWOT Analysis 22.3.7.6. Strategy Overview 22.3.8. Siemens Healthineers AG 22.3.8.1. Overview 22.3.8.2. Product Portfolio 22.3.8.3. Sales Footprint 22.3.8.4. Key Financials 22.3.8.5. SWOT Analysis 22.3.8.6. Strategy Overview 22.3.9. Thermo Fisher Scientific Inc. 22.3.9.1. Overview 22.3.9.2. Product Portfolio 22.3.9.3. Sales Footprint 22.3.9.4. Key Financials 22.3.9.5. SWOT Analysis 22.3.9.6. Strategy Overview 22.3.10. QIAGEN 22.3.10.1. Overview 22.3.10.2. Product Portfolio 22.3.10.3. Sales Footprint 22.3.10.4. Key Financials 22.3.10.5. SWOT Analysis 22.3.10.6. Strategy Overview 23. Assumptions and Acronyms Used 24. Research Methodology
Explore Healthcare Insights
View Reports
Immunochromatography Kits Market
